Navigation Links
Beckman Coulter Elects AMN Healthcare Executive to Board of Directors
Date:12/12/2007

FULLERTON, Calif., Dec. 12 /PRNewswire-FirstCall/ -- Beckman Coulter, Inc. (NYSE: BEC), a leading developer of products that simplify and automate complex biomedical testing, announced today that Susan R. Nowakowski, chief executive officer, president, and director of AMN Healthcare Services, Inc. (NYSE: AHS) has been elected to the board of directors of Beckman Coulter, effective December 10.

(Logo: http://www.newscom.com/cgi-bin/prnh/20031202/BECLOGO )

"Susan is a highly respected business leader with experience in healthcare services, life sciences and venture capital. She has an outstanding record of accomplishments and delivering value for AMN Healthcare shareholders," said Betty Woods, chairman of the Beckman Coulter board of directors. "Her strong leadership, operational and financial skills will be of great value to our board."

Since 2005, Nowakowski has served as CEO of AMN Healthcare Services, the largest healthcare staffing company in the U.S. and the first to exceed $1 billion in annual revenue. Nowakowski has been employed at AMN, in a variety of leadership roles including chief financial officer and chief operating officer, since 1990. Prior to that, she worked at BioVest Partners, a venture capital firm, and at Hybritech, a subsidiary of Eli Lilly that Beckman Coulter later acquired.

Nowakowski also serves on the board of directors of the University of California San Diego Sulpizio Family Cardiovas
'/>"/>

SOURCE Beckman Coulter, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Beckman Coulter to Present at the Bear Stearns Healthcare Conference
2. Beckman Coulter to Present at the UBS Global Life Sciences Conference
3. Beckman Coulter Announces Third Quarter 2007 Earnings to Be Released on Tuesday, October 30, 2007 Before Market Opens
4. Beckman Coulter Declares Quarterly Dividend
5. Beckman Coulter Announces Third Quarter 2007 Results
6. Beckman Coulter to Present at the 19th Annual Piper Jaffray Healthcare Conference
7. Beckman Coulter to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
8. Beckman Coulter to Acquire Exclusive Rights to Break-Through Technologies
9. KGI Elects Three New Members to Board of Trustees
10. The Pittsburgh Life Sciences Greenhouse Elects Four New Members to Its Board of Directors
11. Genaera Elects New Board Member and Announces Executive Appointments

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...OLM, November 20 Karolinska Develo...ent Fund (EIF) has entered into a,co-investment ag...ill be,managed by Karolinska Development and used ...e pharmaceutical and medical technology companies....nvestment fund. The agreement,represents EIF,s lar...
(Date:11/19/2009).... 19 Danish Prince Joachim inaugur...l plant in Kalundborg, Denmark, on Wednesday, Nove...and largest 2nd generation ethanol demonstration b...sed in the plant,s innovative process for converti... was the first to market with commercial enzymes f...
(Date:11/19/2009)... Nov. 19 Spherix Incorpo...ogy for diabetes therapy, and a provider of techni...pplement, biotechnology and pharmaceutical compani...l Meeting of Shareholders. ,, At the meeting, s... ) elected the following members to the Board of D...
(Date:11/19/2009)... World,s Top Gene Synthesis Companies Form Interna...ate Best Practices in Risk Reduction ,Five Membe... Synthesis Capacity , (PR...s leading gene synthesis companies today announced... protocol to promote biosecurity in the gene synth...
Breaking Biology Technology:Karolinska Development and EIF Start Landmark Co-Investment Fund for Life Science Innovation 2Karolinska Development and EIF Start Landmark Co-Investment Fund for Life Science Innovation 3DONG Energy and Inbicon Inaugurate One of the World's Largest Demo Plants for 2nd Generation Biofuel 2Spherix Announces Results of Annual Shareholders Meeting 2Spherix Announces Results of Annual Shareholders Meeting 3Spherix Announces Results of Annual Shareholders Meeting 4World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 2World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 3World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 4
...icals, Inc.,a privately held biopharmaceutical com...ounced new data on its lead product, varespladib (...ual Conference in New Orleans,Louisiana. Anthera h...r the,treatment of coronary heart disease. At the ...ased new data from the Phase II PLASMA-2 study, wh...
...cut,s highest honor for technological achievement,...to Yale Professor Tso-Ping (T.P.) Ma for his pio...ut Medal of Technology is awarded by the Board of ...t Academy of Science and Engineering . It is given...Science and is designed to laud individuals "for s...
...rowth of 12.9 percent,- Full year revenue growth o... and improving profitability reflects success of s...ual financial guidance for fiscal year 2009, BATE...E: HRC ), announced unaudited financial results f...008 -- the second quarter of operations,following ...
Other Biology Technology:Anthera's Varespladib Demonstrates Significant Anti-Inflammatory Effect and LDL Reduction in Patients With Coronary Heart Disease 2Yale professor T.P. Ma awarded the Connecticut Medal of Technology 2Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 2Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 3Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 4Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 5Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 6Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 7Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 8Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 9Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 10Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 11Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 12Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 13Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 14Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 15Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 16Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 17Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 18Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 19
(Date:11/20/2009)...Chronic obstructive pulmonary disease (COPD), a re...itis or emphysema, is the fourth leading cause of ...D and while researchers have yet to find any real ...ch Institute at The University of Western Ontario ...ques to gain new insight into the disease. , ...
(Date:11/19/2009)...It,s a naturally occurring brain chemical with an ...mouth, it can be abused or used as a date-rape dru...s have determined new routes by which 4-HB is meta...formation," said K. Michael Gibson, professor and ...ical University and a member of the research team....
(Date:11/19/2009)...MADISON This week, scientists are revealing the g...ree cereal crops. Corn, or maize, has one of the m...niversity of Wisconsin-Madison genomicist David Sc...e article in the journal Science . , "The maize...and dead-ends that have troubled would-be sequence...
Breaking Biology News(10 mins):Gaining a better picture of lung disease 2Researchers begin to decipher metabolism of sexual assault drug 2Sweet corn story begins in UW-Madison lab 2Sweet corn story begins in UW-Madison lab 3Public Health Faith Leaders Call on DC Council to Renew Funding for Successful Tobacco Prevention Programs 57025 1Public Health Faith Leaders Call on DC Council to Renew Funding for Successful Tobacco Prevention Programs 57025 2Public Health Faith Leaders Call on DC Council to Renew Funding for Successful Tobacco Prevention Programs 57025 3Public Health Faith Leaders Call on DC Council to Renew Funding for Successful Tobacco Prevention Programs 57025 4Enobia Announces Positive Clinical Results With ENB 0040 a Bone Targeted Enzyme Replacement Therapy for Hypophosphatasia 4996 1Enobia Announces Positive Clinical Results With ENB 0040 a Bone Targeted Enzyme Replacement Therapy for Hypophosphatasia 4996 2Enobia Announces Positive Clinical Results With ENB 0040 a Bone Targeted Enzyme Replacement Therapy for Hypophosphatasia 4996 3National Certification for Medical Interpreters Public Call for Final Written Pilot Exam 57018 1National Certification for Medical Interpreters Public Call for Final Written Pilot Exam 57018 2
...d a novel method for attaching small molecules, su...re used to capture large biomolecules. By varying...s, researchers can make the technique applicable t...chemical warfare agents, and environmental polluta...ntify synthetic biomolecules that recognize neurot...
...ity of Pennsylvania and Johns Hopkins University h...ommonly activated proteins in cancer is so dangero... Myc protein can stop the production of at least 1...p control which genes are turned on and off., Fur...ressed miRNAs ,into Myc-containing cancer cells su...
...th the designation of Threatened by the Committee ...SEWIC). COSEWIC is the scientific body that advise...at risk. , Since 1967, the number of chimney swi...y swifts are sooty-coloured, swallow-like birds th...rick-lined chimneys. From late April to early Octo...
Other Biology News:Biocapture surfaces produced for study of brain chemistry 2University of Pennsylvania researchers zero in on the tiniest members in the war on cancer 2
Experion RNA StdSens Chips, 10 from Bio-Rad
MiniMACS Separation Unit from Miltenyi Biotec
Experion RNA HighSens Chips, 10 from Bio-Rad
...activated with carbonyl diimidazole chemistry that...e PS10 array contains the same binding chemistry a...hobic barrier coating. These arrays are 8 spot chi...ith one column of a standard 96-well microplate (9...
Biology Products: